B
Bijesh K. Biswal
Researcher at National Institute of Technology, Rourkela
Publications - 32
Citations - 573
Bijesh K. Biswal is an academic researcher from National Institute of Technology, Rourkela. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 10, co-authored 27 publications receiving 309 citations. Previous affiliations of Bijesh K. Biswal include Indian Institute of Technology Madras & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Emerging role of plumbagin: Cytotoxic potential and pharmaceutical relevance towards cancer therapy.
TL;DR: Nano encapsulation of plumbagin overcomes the poor water solubility and bioavailability obstacles, enhancing the pharmaceutical relevance with better therapeutic efficacy and can be introduced as a future phytotherapeutic anticancer drug after fully satisfied preclinical and clinical trials.
Journal ArticleDOI
Cell signaling and cancer: a mechanistic insight into drug resistance
Munmun Panda,Bijesh K. Biswal +1 more
TL;DR: This review outlines the different mechanisms enabling resistance including drug efflux, drug target alternation, alternative splicing, the release of the extracellular vesicle, tumor heterogeneity, epithelial-mesenchymal transition, tumor microenvironment, and the secondary mutation in the receptor.
Journal ArticleDOI
Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
TL;DR: Piperlongumine, a white to beige biologically active alkaloid/amide phytochemical, has high pharmacological relevance as an anticancer agent in both preclinical and clinical settings as discussed by the authors.
Journal ArticleDOI
Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation.
Bijesh K. Biswal,Maroun J. Beyrouthy,Mary P. Hever-Jardine,David A. Armstrong,Craig R. Tomlinson,Brock C. Christensen,Carmen J. Marsit,Michael J. Spinella +7 more
TL;DR: It is shown here that low-dose 5-aza treatment results in DNA damage and induction of p53 in NT2/D1 cells and results in global and gene specific promoter DNA hypomethylation in p53 and pluripotency genes.
Journal ArticleDOI
Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate.
TL;DR: This study has shown that receptor mediated delivery of siRNA enables silencing of target genes in specific tissues and can be extended to deliver a wide range of drugs and post-transcriptional gene silencing therapeutics.